Acute Coronary Syndrome Market Outlook Report 2024-2033 | Trends, Analysis, Insights, and Overview

"The new report published by The Business Research Company, titled Acute Coronary Syndrome Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the acute coronary syndrome market size has grown strongly in recent years. It will grow from $9.23 billion in 2023 to $9.86 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The acute coronary syndrome market size is expected to see strong growth in the next few years. It will grow to $12.44 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12985&type=smp

Rising Prevalence Of Chronic Diseases Fuels Growth In The Acute Coronary Syndrome Market
The increasing prevalence of chronic diseases such as coronary artery disease, ischemic heart disease and vascular diseases is expected to propel the growth of the acute coronary syndrome market going forward. Ischemic heart disease is a chronic disease caused by the obstruction or narrowing of the coronary arteries. The treatment of acute coronary syndrome (ACS) is aimed at promptly relieving symptoms, minimizing heart damage and preventing further complications for patients suffering from various acute coronary syndromes, including ischemic heart disease and vascular diseases. For instance, in August 2022, according to a study published in the Journal of the American College of Cardiology, a US-based organization, all four cardiovascular risk factors are anticipated to rise among the general U.S. population between 2025 and 2060, dyslipidemia increased by 27.6%, and hypertension by 25.1%. The researchers discovered that heart failure (33.4%) and ischemic heart disease (30.7%) had the biggest anticipated increases in rates, followed by heart attack (16.9%) and stroke (33.8%). Therefore, the prevalence of chronic diseases such as coronary artery disease, ischemic heart disease and vascular diseases drives the acute coronary syndrome market.

Innovative Drug Development Fuels Advancements In Acute Coronary Syndrome Treatment
Major companies operating in the acute coronary syndrome market are developing innovative drugs to treat acute coronary syndrome and sustain their position in the market. The advancements in drug development can increase the efficiency of ACS treatment, reducing the time and resources required for each patient. For instance, in June 2023, AGEPHA Pharma USA LLC, a US-based pharmaceutical company, launched Lodoco, which was approved by the Food and Drug Administration (FDA), a US-based government agency. This is the first anti-inflammatory atheroprotective cardiovascular treatment that reduces the risk of heart stroke, coronary revascularization, myocardial infarction (MI) and cardiovascular death in adult patients with cardiovascular diseases, including acute coronary syndrome.

The acute coronary syndrome market covered in this report is segmented -

1) By Type: Non-St-Elevation Myocardial Infarction; St-Elevation Myocardial Infarction; Unstable Angina
2) By Treatment: Medications; Statins; Beta blockers; ACE inhibitors; Anticoagulants; Other Treatment
3) By Diagnosis: Stress Test; Blood Tests; Imaging; Other Diagnosis
4) By Route Of Administration: Oral; Parenteral
5) By End-User: Hospitals; Specialty clinics; Other End User

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12985&type=discount

Major players in the acute coronary syndrome market are Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Terumo Corp., BioMérieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc.

Contents of the report:
1. Executive Summary
2. Acute Coronary Syndrome Market Report Structure
3. Acute Coronary Syndrome Market Trends And Strategies
4. Acute Coronary Syndrome Market - Macro Economic Scenario
5. Acute Coronary Syndrome Market Size And Growth
…..
27. Acute Coronary Syndrome Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

"Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."

This release was published on openPR.